ES2930093T3 - Antagonistas de TNFR1 y agonistas de TNFR2 dobles para uso en enfermedades renales - Google Patents

Antagonistas de TNFR1 y agonistas de TNFR2 dobles para uso en enfermedades renales Download PDF

Info

Publication number
ES2930093T3
ES2930093T3 ES20207534T ES20207534T ES2930093T3 ES 2930093 T3 ES2930093 T3 ES 2930093T3 ES 20207534 T ES20207534 T ES 20207534T ES 20207534 T ES20207534 T ES 20207534T ES 2930093 T3 ES2930093 T3 ES 2930093T3
Authority
ES
Spain
Prior art keywords
stnfr1
compound
tnfr1
treatment
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20207534T
Other languages
English (en)
Spanish (es)
Inventor
Eva Steiness
Torben Frank Skarsfeldt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serodus AS
Original Assignee
Serodus AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serodus AS filed Critical Serodus AS
Application granted granted Critical
Publication of ES2930093T3 publication Critical patent/ES2930093T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES20207534T 2020-11-13 2020-11-13 Antagonistas de TNFR1 y agonistas de TNFR2 dobles para uso en enfermedades renales Active ES2930093T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20207534.7A EP4000615B1 (en) 2020-11-13 2020-11-13 Dual tnfr1 antagonists and tnfr2 agonists for use in renal diseases

Publications (1)

Publication Number Publication Date
ES2930093T3 true ES2930093T3 (es) 2022-12-07

Family

ID=73448924

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20207534T Active ES2930093T3 (es) 2020-11-13 2020-11-13 Antagonistas de TNFR1 y agonistas de TNFR2 dobles para uso en enfermedades renales

Country Status (9)

Country Link
US (1) US12083097B2 (pl)
EP (1) EP4000615B1 (pl)
JP (1) JP7462116B2 (pl)
CN (1) CN116568296A (pl)
AU (1) AU2021378077B2 (pl)
CA (1) CA3197986A1 (pl)
ES (1) ES2930093T3 (pl)
PL (1) PL4000615T3 (pl)
WO (1) WO2022101389A1 (pl)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976509B1 (en) * 2006-01-18 2014-12-17 Evolva SA Ppar modulators
AU2008206050B2 (en) 2007-01-18 2014-08-14 Evolva Sa Prodrugs of substituted 1,3-dioxanes and their uses
ES2609825T3 (es) * 2007-01-18 2017-04-24 Evolva Sa 1,3-Dioxanos sustituidos útiles como moduladores de PPAR
EP2934513A2 (en) * 2012-12-18 2015-10-28 Evolva SA Treatment of cardiovascular risk in diabetic patients
WO2015193630A1 (en) * 2014-06-18 2015-12-23 Evolva Sa Treatment of cardiovascular risk in patients with cardiovascular disease and/or diabetes
CN111825547B (zh) * 2019-04-23 2022-04-19 南京海融医药科技股份有限公司 一种芳基丙酸类化合物的盐及其制药用途

Also Published As

Publication number Publication date
EP4000615A1 (en) 2022-05-25
WO2022101389A1 (en) 2022-05-19
EP4000615B1 (en) 2022-10-19
AU2021378077B2 (en) 2024-03-14
US12083097B2 (en) 2024-09-10
CN116568296A (zh) 2023-08-08
AU2021378077A1 (en) 2023-05-25
JP7462116B2 (ja) 2024-04-04
PL4000615T3 (pl) 2022-12-19
US20230414562A1 (en) 2023-12-28
CA3197986A1 (en) 2022-05-19
JP2023554588A (ja) 2023-12-28

Similar Documents

Publication Publication Date Title
ES2913225T3 (es) Acido valproico para el tratamiento o prevención de afecciones patológicas asociadas con deposición de fibrina en exceso y/o formación de trombos
BR112015005783B1 (pt) Análogos de glucagon
ES2657943T3 (es) Inhibidores de VAP-1 para el uso en el tratamiento de afecciones fibróticas
Worcester et al. A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I
CA2666629C (en) Use of il-1 antagonists to treat gout and pseudogout
ES2930093T3 (es) Antagonistas de TNFR1 y agonistas de TNFR2 dobles para uso en enfermedades renales
JP2024513502A (ja) Ｕｒａｔ１阻害剤、医薬組成物及びその使用
JP2008031164A (ja) 高尿酸血症又はこれに起因する疾患の予防又は治療のための医薬組成物
JP2007055900A (ja) 炎症性疾患の治療及び予防用医薬組成物
WO2022159566A1 (en) Benzenesulfonamide agonists of trap1 for treating organ fibrosis
Lei et al. A4480 Chronic treatment with a SGLT2 inhibitor does not activate systemic and intrarenal renin-angiotensin system in CKD rats
Juan et al. A6695 Effects of high sodium on the proliferation and phenotype transformation of rat cardiac fibroblasts cells
Klimov et al. A2140 Antisense containing nanocomposites in hypertension treatment in ISIAH rats
CN104610190B (zh) 一类含环丙基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途
ES2307933T3 (es) Proteina de 35 kda.
CN104628671B (zh) 含苯基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途
Saleh Role of Endothelin-1 (ET-1) in Glomerular Inflammation and Glomerular Permeability in Normal and Diabetic Kidneys
Benaissa et al. THE INFLUENCE OF COCONUT MILK ON THE INTESTINAL STRUCTURE OF BALB/C MICE IMMUNIZED WITH COW'S MILK PROTEINS
Peceliuniene et al. THE RELATIONSHIP OF GLUCOSE TOLERANCE TEST RESULTS WITH MAJOR CARDIOVASCULAR EVENTS AND NEUROPSYCHIATRIC DISORDERS BY MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW IN PRIMARY CARE
Avdonina et al. VASCULAR STIFFNESS IN TRUE RESISTANT HYPERTENSIVE PATIENTS AFTER RENAL DENERVATION: DOES PLASMA ALDOSTERONE MATTER?
Mihalcea et al. MEN 2A SYNDROME–A SURPRISING CAUSE FOR SECONDARY HYPERTENSION
Marusakova et al. COLA BEVERAGE-INDUCED METABOLIC SYNDROME IS CHARACTERISED BY ALTERED LEVELS OF LEPTIN, GHRELIN AND OBESTATIN
Reijnen et al. Rebound phenomenon in tissue plasminogen activator activity of parietal peritoneum after anastomosing colon in rats with bacterial peritonitis
Fellner Prouroguanylin's role in the homeostatic response to dietary sodium: Hormone precursor or active signaling agent?
Amosova et al. PP. 19.28: EFFICACY OF STANDARDIZED ALGORITHMIC TREATMENT FOR OFFICE AND HOME BLOOD PRESSURE CONTROL IN NORMAL-WEIGHT, OVERWEIGHT AND OBESE HYPERTENSIVES IN LONGITUDINAL REAL-LIFE STUDY